Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of compound to preparation of medicines for treating viral pneumonia

A technology for viral pneumonia and compounds, applied in the field of medicine, can solve problems such as lack of new antiviral drugs, and achieve the effects of superior antiviral pneumonia effect, simple preparation method and significant activity

Active Publication Date: 2020-06-05
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF8 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] One of the purposes of the present invention is to propose the application of a compound in the preparation of drugs for the treatment of viral pneumonia, which solves the technical problem of lack of new antiviral drugs in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound to preparation of medicines for treating viral pneumonia
  • Application of compound to preparation of medicines for treating viral pneumonia
  • Application of compound to preparation of medicines for treating viral pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] This example provides the effect of combined drugs on coronavirus pneumonia.

[0025] Experimental method: C57BL / 6 mice (20-25g) were randomly divided into 5 groups according to different body weights, namely: group A, blank control group; group B, HcoV-OC43 virus model group; group C, HcoV-OC43 virus model group Compound 1 group; D group, HcoV-OC43 virus compound 2 group; E group, HcoV-OC43 virus compound 1 and 2 combination group (low dose); F group, HcoV-OC43 virus compound 1 and 2 combination group (high dose) ; Group G, positive drug ribavirin group; H group, positive drug oseltamivir group. Animals in all groups were anesthetized with propofol tail vein, except for the blank control group, they were all infected with HcoV-OC43 virus solution (30 μL) by intranasal drip.

[0026] Subsequent processing is as follows:

[0027] Group A mice: intragastric administration of the same dose of normal saline in the drug intervention group;

[0028] Group B mice: intragast...

Embodiment 2

[0042] This example provides the effect of combined drugs on influenza A virus pneumonia.

[0043] Experimental method: C57BL / 6 mice (20-25g) were randomly divided into 5 groups according to body weight: Group A, blank control group, group B, HcoV-OC43 virus model group, group C, HcoV-OC43 virus compound Group 1, group D, HcoV-OC43 virus compound group 2, group E, HcoV-OC43 virus compound 1 and 2 combination group (low dose), F group, HcoV-OC43 virus compound 1 and 2 combination group (high dose), Group G, positive drug ribavirin group, group H, positive drug oseltamivir group. Animals were anesthetized with propofol through the tail vein, and were infected with H1N1 virus solution (30 μL) by intranasal drip except for the blank control group. Subsequent operations:

[0044] Group A mice: The intervention group was given the same dose of normal saline by intragastric administration of drugs;

[0045] Group B mice: intragastric administration of drugs to give the interventio...

Embodiment 3

[0059] This example provides a synthesis method of the purine compound (1-ethyl-3-7-dimethylxanthine) with the structure of formula 1.

[0060] Take 540mg (3mmoL) of theobromine and 720mg (30mmol) of NaH dissolved in 80mL of DMF, and add 2mL of iodoethane (24.7mmol) dropwise under stirring. After reacting for 4 hours, add water to quench the reaction, spin dry under reduced pressure, and separate on a silica gel column (mobile phase; petroleum ether: CH 3 CH 2 OCOCH 3 =3:1) The product compound 1-ethyl-3-7-dimethylxanthine (495mg, 2.5mmol, 85%) was obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a compound to preparation of medicines for treating viral pneumonia, and relates to the technical field of drugs. The technical problem that novel antiviral drugs are deficient in the prior art, can be solved. The compound comprises a purine compound adopting the structure as shown in the formula 1, and / or an anthraquinone derivative adopting the structureas shown in the formula 2. The purine compound adopting the structure as shown in the formula 1, and / or the anthraquinone derivative adopting the structure as shown in the formula 2 both can show predominant effect for resisting viral pneumonia when being separately used or used jointly. Drugs for treating viral pneumonia, are prepared by the compound provided by the invention are more notable inactivity compared with clinical frontline drugs, and are better than drugs of ribavirin, oseltamivir and the like.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a compound in the preparation of a drug for treating viral pneumonia. Background technique [0002] Viral pneumonia is an inflammation of the lungs caused by the downward spread of a virus infected by the upper respiratory tract. Viral pneumonia can occur at any time of the year, but it breaks out and becomes popular in winter and spring. The main clinical manifestations are fever, headache, body aches, dry cough, and lung infiltration. The incidence of viral pneumonia is often related to the virulence of the virus, the route of infection, the age of the host, and the immune status. The disease occurs more frequently in the elderly and children. In the case of acute respiratory infection, the virus infection rate can be as high as 90%, and the upper respiratory tract infection is the main route, which is divided into diseases such as common cold, pharyngitis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/522A61K31/122A61P31/16A61P31/14A61P11/00
CPCA61K31/122A61K31/522A61P11/00A61P31/14A61P31/16A61K2300/00
Inventor 黄文张伯礼李幼平张俊华钮海辛光
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com